We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Proton Therapy Lowers Risk of Later Cancers

By HospiMedica International staff writers
Posted on 20 Oct 2008
Patients who are treated with proton therapy (a specialized type of external beam radiation therapy using protons rather than X-rays to treat cancer) have a decreased risk of developing a secondary cancer by two-fold, compared to being treated with conventional photon radiation treatment, according to a first-of-its-kind study.

This study, presented September 22, 2008, at the American Society for Therapeutic Radiology and Oncology's 50th annual meeting in Boston, MA, USA, contradicts recent hypotheses that have suggested that proton radiation might actually increase--instead of decrease--the incidence of secondary cancers because of what is called scatter radiation. More...
When proton radiation is delivered, neutrons are produced by nuclear interactions and are therefore scattered as a result.

"This study could have a substantial impact on the care of patients,” said Nancy Tarbell, M.D., senior author of the study and a radiation oncologist at the Massachusetts General Hospital (MGH; Boston, MA, USA). "Since cancer patients are surviving for longer periods of time, side effects of therapy are becoming increasingly important for doctors to consider when developing treatment plans. Since this is a retrospective study, however, we will need additional studies to further prove this hypothesis.”

Photon radiation is the standard external beam radiation-therapy treatment, whereas proton radiation is a more targeted form of external beam radiation that delivers less radiation to bordering normal structures. During external beam radiation therapy, a beam of radiation is directed through the skin to the cancer and the immediate surrounding area in order to destroy the main tumor and any neighboring cancer cells.

The retrospective cohort study matched 503 patients who underwent Harvard (Cambridge, MA, USA) Cyclotron proton radiation treatment with 1,591 patients treated with photon radiation therapy from the Surveillance, Epidemiology, and End Results (SEER) cancer registry from 1974 to 2001. According to the study, 6.4% of patients who underwent proton therapy developed a secondary cancer while 12.8% of patients who had photon treatment developed another type of cancer.

Related Links:

Massachusetts General Hospital


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.